A carregar...
In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies
Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus spp., including azole–susceptible and azole–r...
Na minha lista:
| Publicado no: | J Fungi (Basel) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8003840/ https://ncbi.nlm.nih.gov/pubmed/33804780 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jof7030232 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|